Osaka University Venture Capital

Ayumo is a technology company specializing in AI-driven healthcare solutions. It offers a platform that leverages medical knowledge and AI to assist doctors in diagnoses, suggest examination sequences, and detect locomotive syndrome. The platform also provides users with wellbeing consultations and recovery recommendations, promoting digital transformation in the medical field.

RegCell is a biotechnology company focused on developing innovative therapeutic technologies to address autoimmune diseases and cancer. The company specializes in creating advanced cell therapies that work by controlling and augmenting the immune system. RegCell's approach involves returning regulatory T cells and activating them in vitro, allowing for effective treatment options for patients facing these challenging health conditions. By targeting unmet medical needs, RegCell aims to improve patient outcomes and provide new hope for those suffering from autoimmune disorders and cancer.

QunaSys is a company focused on advancing the practical application of quantum technology through the development of algorithm and application software. Established to harness the potential of quantum physics, QunaSys aims to illuminate the underlying quantum phenomena that influence various technologies, from semiconductors to medical imaging. Their platform enables the simulation of quantum mechanical behaviors, allowing researchers to effectively execute quantum chemistry calculations on both quantum computers and simulators. By bridging the gap between theoretical quantum physics and real-world applications, QunaSys seeks to facilitate innovations that were previously unattainable with conventional technologies, thereby contributing to the evolution of quantum computing and its related fields.

A-Wave is a manufacturing company specializing in medical devices. It develops and markets innovative solutions, including a remote medical treatment system featuring a wristwatch-type wearable device. This device detects cardiac murmurs, reduced activity, and peripheral colds, enabling early symptom detection of heart failure in patients at home.

Alpha Fusion specializes in the development of astatine-based radiopharmaceuticals aimed at targeted alpha therapy for cancer treatment. The company focuses on drug discovery and business development of low-molecular-weight and antibody-introduced astatine compounds. By leveraging alpha-ray nuclear medicine therapy, Alpha Fusion seeks to offer innovative solutions for healthcare providers in their efforts to cure cancer.

Luxna Biotech Co., Ltd., founded in 2017 and headquartered in Suita, Japan, specializes in the development of nucleic acid drugs. The company employs innovative technologies to expedite the practical application of these drugs, offering drug discovery support services that leverage artificial nucleic acid technology. Its mission is to alleviate suffering by contributing to improved medical treatments.

Celaid Therapeutics is a regenerative medicine company focused on the development and commercialization of cell therapy products derived from human hematopoietic stem cells. The company employs advanced stem cell expansion technology to create innovative therapies, while also offering research and discovery support through specialized media reagents. Celaid Therapeutics aims to enhance medical practices in hematopoietic stem cell transplantation and cell therapy, incorporating gene-editing technology to improve treatment outcomes. By leveraging its expertise, the company addresses critical needs in regenerative medicine, providing valuable solutions for medical professionals.

Developer of a healthcare technology designed to replace the traditional way of treating cancer treatment. The company aims to transform the traditional therapeutic into a next-generation therapy for cancer diseases by maximizing the drug potency with minimum toxicity, helping the healthcare sector to overcome systemic toxicity and exhibiting strong anti-tumor efficacy in various tumor models both as monotherapy and in combination with immune checkpoint inhibitors.

Restore Vision is a biotechnology company focused on developing innovative therapies for eye diseases, particularly retinitis pigmentosa. The company specializes in gene therapy that employs advanced chimeric rhodopsin genes, which enhance the functionality of conventional rhodopsins. This technology aims to address the limitations of traditional treatments, providing high sensitivity and improved outcomes for patients suffering from intractable eye conditions. Through its research and development efforts, Restore Vision seeks to create effective therapeutic agents that significantly contribute to the field of ocular health.

Thinker provides sales of proximity sensors and proposed solutions using these products.

EX-Fusion is focused on developing and operating the world's first laser-powered commercial nuclear fusion reactor, aiming to provide a sustainable energy solution. The company specializes in the manufacture of continuous plasma generators and is involved in laser-plasma research, offering technology and R&D support for fusion systems. By advancing the practical application of laser fusion, EX-Fusion seeks to overcome the challenges often faced by government-funded fusion research, which can be hindered by shifting political priorities and budget constraints. Through its innovative approach, EX-Fusion aims to contribute significantly to the field of clean energy.

GAIA BioMedicine Inc. is a biopharmaceutical company based in Fukuoka Prefecture, Japan, founded in 2015 as a spin-off from Kyushu University. The company focuses on developing regenerative medicine products, specifically specializing in cell treatments and immunotherapies aimed at addressing intractable malignancies. GAIA BioMedicine utilizes advanced technologies to harness the power of genes and the immune system, providing innovative solutions to combat difficult-to-treat cancers. Through its commitment to leveraging cutting-edge research and development, GAIA BioMedicine strives to improve patient outcomes in the fight against challenging diseases.

GAIA BioMedicine Inc. is a biopharmaceutical company based in Fukuoka Prefecture, Japan, founded in 2015 as a spin-off from Kyushu University. The company focuses on developing regenerative medicine products, specifically specializing in cell treatments and immunotherapies aimed at addressing intractable malignancies. GAIA BioMedicine utilizes advanced technologies to harness the power of genes and the immune system, providing innovative solutions to combat difficult-to-treat cancers. Through its commitment to leveraging cutting-edge research and development, GAIA BioMedicine strives to improve patient outcomes in the fight against challenging diseases.

SK Fine is a pioneering company in the field of 3D printing technology, specifically focused on ceramics. It is recognized as the first to introduce a 3D printer for ceramics to the Japanese market. The company specializes in creating ceramic parts that traditional manufacturing methods cannot produce, utilizing three-dimensional CAD data provided by clients. SK Fine not only offers customized products from various materials, including resin and metal, but also develops tailored 3D printing processes for ceramic components to meet specific client requirements. Through its innovative approach, SK Fine is advancing the capabilities of ceramic manufacturing, providing unique solutions that cater to diverse needs in the industry.

JiMED is a company focused on developing wireless embedded brain-computer interface (BCI) systems that facilitate the reading of brain activity. It offers a wireless implantable BCI system that utilizes an implanted device combined with artificial intelligence to interpret neural signals. This innovative technology enables individuals, particularly those suffering from ALS, to communicate more effectively and improve their quality of life by allowing them to operate the device through thought alone.

Immunosens is a developer of electrochemical measurement devices focused on evaluating biomarkers, including genes, proteins, and cell signals through electrode reactions. The company specializes in the production of sensors that utilize disposable printable electrodes, which enhance the accuracy of analyses and measurements. These devices are aimed at supporting healthcare professionals in their diagnostic processes as well as in food safety inspections, providing reliable and precise results essential for effective decision-making in various applications.

HULIX Technologies specializes in the development and sale of human flow space analysis platforms that facilitate the understanding of human behavior and spatial dynamics. The company's offerings include Human Navigation Research, which automatically gathers and visualizes data on human behavior to identify underlying issues, and the Hitonavi Cloud suite, which supports people flow surveys and verifications. Hitonavi Cloud Advanced utilizes collected data to enhance applications in various sectors, including marketing, smart cities, security, and energy management. Additionally, HULIX's digital twin platform aims to bridge the gap between the physical and digital worlds, enabling both humans and AI to navigate real-world environments effectively. By focusing on creating a human-centered environment, HULIX Technologies addresses social challenges and promotes the smart development of modern society and industry.

Aipore Inc. is a technology company based in Shibuya-ku, Tokyo, Japan, that specializes in the development of nanopore sensors. Founded in 2018, Aipore utilizes semiconductor microfabrication technology to create Internet of Things (IoT) sensors capable of measuring and analyzing changes in ion flow. The company's innovative technology integrates various advancements, including silicon micro-electromechanical systems (MEMS), flow path surface control, and low noise amplification circuits. By employing artificial intelligence, Aipore's sensors can accurately identify particles such as viruses and microorganisms, making them suitable for a range of industrial applications, including laboratory testing, cancer detection, blood diagnostics, livestock inspection, and environmental assessment. The company aims to revolutionize fine particle measurement and enhance analytical capabilities across multiple sectors.

COTOBADESIGN, Inc. specializes in the development and delivery of dialogue artificial intelligence (AI) content. Established in 2017 and headquartered in Tokyo, Japan, the company offers innovative tools aimed at enhancing productivity in various sectors, including elderly and nursing care, business automation, and entertainment. Additionally, COTOBADESIGN provides a platform that supports the development of dialogue AI content, catering to the growing demand for automated communication solutions across different markets.

Periotherapia is a drug discovery company focused on developing medical treatments for intractable diseases, with a primary emphasis on triple-negative breast cancer. The company aims to selectively inhibit specific pathways involved in disease progression without affecting physiological processes associated with chronic conditions such as cancer, heart failure, arteriosclerosis, renal failure, and diabetic retinopathy. By utilizing disease-specific antibodies, Periotherapia contributes to early diagnosis and precision medicine, enhancing the ability of healthcare professionals to identify and create new therapeutic options for various challenging medical conditions.

GlyTech, Inc. is a biotechnology company based in Kyoto, Japan, founded in 2012. It specializes in the manufacture of human-type N-glycans and employs advanced glycosylation technologies for glycopeptide and glycoprotein synthesis. The company is dedicated to producing natural glycoproteins and glycopeptides through both glycoscience and chemical synthetic methods. GlyTech provides a range of services, including licensing of glycosylated peptides and proteins, contract research and development, custom synthesis, and contract manufacturing. Additionally, it supplies standard reagents, supporting researchers in their efforts to advance human health, enhance drug development options, and expand capabilities in biotherapeutic analysis and glycoscience research.

J-Pharma is a pharmaceutical company dedicated to improving human health by developing novel drugs based on a human-genomic approach. The company focuses on creating selective agents to treat specific diseases, with an emphasis on cell membrane transporters closely associated with various illnesses. J-Pharma's intellectual property includes the discovery of important drug transporters within the human body, which can be used to evaluate and optimize the pharmacokinetics of new drug candidates. Their pipeline aims to produce new therapeutic agents and diagnostic methods, particularly targeting cancer treatment through drugs like anti-cancer agents and PET diagnostic agents against LAT1. The company's ultimate goal is to enhance the quality of life for an aging population in industrialized countries and contribute globally to human welfare.

PGV Co., Ltd., founded in September 2016 and based in Japan, specializes in the development of electroencephalogram (EEG) related technologies. The company focuses on creating innovative brain wave sensor devices, specifically patch-type electroencephalographs, which allow for the accurate measurement of brain waves in a manner similar to using a thermometer. By integrating artificial intelligence for data analysis, PGV aims to facilitate self-care through the continuous monitoring of brain activity, thereby enhancing personal health management. The company's advancements are designed to support medical professionals in delivering efficient and effective patient care through accurate data collection and machine learning applications.

ThinkCyte, Inc. is a biotechnology company that specializes in developing an artificial intelligence-enabled, image-free visual cell sorting system, which sorts cells based on their morphology. Founded in 2016 and headquartered in Tokyo, Japan, with an additional office in San Carlos, California, ThinkCyte utilizes advanced optics and machine learning to create its ghost cytometry technology. This innovative approach allows for ultra-high throughput and content-rich analysis of single cells, facilitating research, diagnostics, and therapeutics across various medical disciplines such as drug discovery and cell therapy. The company's cell sorting technology enables researchers to identify and isolate specific cells, including rare ones, in real-time, advancing the capabilities of single-cell analysis.

Kringle Pharma, Inc. is a biopharmaceutical company based in Ibaraki, Japan, founded in 2001. The company specializes in the research and development of hepatocyte growth factor (HGF) protein medicines, which have regenerative healing properties for liver cells and other organs. Kringle Pharma focuses on creating HGF products aimed at treating a range of conditions, including acute spinal cord injury, amyotrophic lateral sclerosis (ALS), acute kidney injury associated with ALS, and vocal fold scars. Additionally, the company explores the therapeutic potential of NK4, a bi-functional molecule that acts as an HGF-antagonist with antiangiogenic properties, targeting cancer therapies. Kringle Pharma's innovative approach positions it at the forefront of developing treatments for intractable diseases.

Luxna Biotech Co., Ltd., founded in 2017 and headquartered in Suita, Japan, specializes in the development of nucleic acid drugs. The company employs innovative technologies to expedite the practical application of these drugs, offering drug discovery support services that leverage artificial nucleic acid technology. Its mission is to alleviate suffering by contributing to improved medical treatments.

PGV Co., Ltd., founded in September 2016 and based in Japan, specializes in the development of electroencephalogram (EEG) related technologies. The company focuses on creating innovative brain wave sensor devices, specifically patch-type electroencephalographs, which allow for the accurate measurement of brain waves in a manner similar to using a thermometer. By integrating artificial intelligence for data analysis, PGV aims to facilitate self-care through the continuous monitoring of brain activity, thereby enhancing personal health management. The company's advancements are designed to support medical professionals in delivering efficient and effective patient care through accurate data collection and machine learning applications.

Remohab Corporation, established in 2017 and based in Suita City, Japan, specializes in remote telemedicine solutions focused on cardiac rehabilitation. The company has developed an innovative system that enhances the rehabilitation process by integrating Internet of Things (IoT) and Information and Communication Technology (ICT). This system enables patients to engage in rehabilitation activities at home while remaining monitored by healthcare professionals at remote medical institutions. By facilitating a connection between home and hospital-based care, Remohab aims to improve patient outcomes and support effective health management for individuals recovering from cardiac issues.

mediVR, Inc. is a Tokyo-based company focused on developing and manufacturing therapeutic medical devices that leverage virtual reality, three-dimensional tracking, and artificial intelligence technologies to enhance rehabilitation programs. Founded in 2016, the company offers mediVR Kagura, a self-exercise device designed to assess motor function, posture balance, and cognitive skills essential for walking. This innovative platform facilitates various body movement exercises through engaging games and activities, utilizing a base station, virtual reality headset, and handheld controllers. By marketing its device via a network of distributors, mediVR aims to support clinicians and families in accelerating rehabilitation for patients, particularly those recovering from strokes. The company also has an office in Osaka, further extending its reach in the healthcare sector.

Immunosens is a developer of electrochemical measurement devices focused on evaluating biomarkers, including genes, proteins, and cell signals through electrode reactions. The company specializes in the production of sensors that utilize disposable printable electrodes, which enhance the accuracy of analyses and measurements. These devices are aimed at supporting healthcare professionals in their diagnostic processes as well as in food safety inspections, providing reliable and precise results essential for effective decision-making in various applications.

Cykinso, Inc., founded in 2014 and based in Kawasaki-Shi, Japan, specializes in developing and selling direct-to-consumer microbiome testing kits. The company offers a home-testing solution that assesses the state of an individual's intestinal bacteria. Utilizing advanced sequencing technology, Cykinso's kit rapidly analyzes a vast number of DNA sequences to provide users with insights into their gut health. This information helps individuals understand the relationship between their intestinal flora and various lifestyle-related and digestive diseases, enabling them to make informed health decisions based on their gut microbiome data.

MiCAN Technologies Inc. is a biotechnology company based in Kyoto, Japan, specializing in the production and supply of blood cells for research purposes, utilizing regenerative medicine technology. Founded in 2016, the company focuses on developing new drug therapies for infectious diseases, particularly malaria and dengue. MiCAN Technologies offers specific products such as MPV, a red blood-like cell tailored for malaria research, and M02, a myeloid lineage cell designed for dengue research. By creating homogeneous and stable experimental blood cells, MiCAN Technologies aims to streamline drug development processes and enhance the evaluation of drug safety and efficacy, ultimately contributing to the fight against infectious diseases.

AI Samurai Inc. is a Tokyo-based company founded in 2015 that focuses on the development and sale of artificial intelligence technology. The company specializes in creating a patent examination platform that utilizes AI to evaluate patentability and conduct comprehensive patent searches. This platform supports clients in analyzing patent documents, thereby facilitating research and development efforts. In addition to its core offerings, AI Samurai also engages in patent research and technical investigation, providing valuable insights and services to enhance innovation in the field of artificial intelligence. The company also maintains a branch office in Osaka, expanding its reach within Japan.

Telenoid Healthcare Company Ltd. is a Tokyo-based firm founded in 2015, specializing in innovative solutions for elderly individuals with dementia. The company has developed Terenoid, an app designed to enhance communication between dementia patients and their caregivers through a remote-controlled device equipped with a camera and microphone. Additionally, Telenoid offers the Chatter Box, a consulting service that provides nursing care leaders with a knowledge database to facilitate conversations and improve care practices. This service aids junior staff by allowing them to input and access personality data about seniors, thus fostering a better understanding of their perspectives. Telenoid’s commitment to enhancing the quality of care for the elderly is reflected in its multifaceted approach, which includes applications for research and training in nursing homes.

Periotherapia is a drug discovery company focused on developing medical treatments for intractable diseases, with a primary emphasis on triple-negative breast cancer. The company aims to selectively inhibit specific pathways involved in disease progression without affecting physiological processes associated with chronic conditions such as cancer, heart failure, arteriosclerosis, renal failure, and diabetic retinopathy. By utilizing disease-specific antibodies, Periotherapia contributes to early diagnosis and precision medicine, enhancing the ability of healthcare professionals to identify and create new therapeutic options for various challenging medical conditions.

PaMeLa Co., Ltd. is a medical device company based in Suita, Japan, founded in 2016. The company focuses on developing innovative technology to measure pain experienced by patients during surgical procedures. By utilizing brain wave analysis, algorithms, and machine learning, PaMeLa aims to create an objective method for quantifying pain. This approach is intended to enhance medical care by providing a scientific basis for pain assessment, thereby improving patient outcomes and treatment strategies.

ThinkCyte, Inc. is a biotechnology company that specializes in developing an artificial intelligence-enabled, image-free visual cell sorting system, which sorts cells based on their morphology. Founded in 2016 and headquartered in Tokyo, Japan, with an additional office in San Carlos, California, ThinkCyte utilizes advanced optics and machine learning to create its ghost cytometry technology. This innovative approach allows for ultra-high throughput and content-rich analysis of single cells, facilitating research, diagnostics, and therapeutics across various medical disciplines such as drug discovery and cell therapy. The company's cell sorting technology enables researchers to identify and isolate specific cells, including rare ones, in real-time, advancing the capabilities of single-cell analysis.

C4U Co., Ltd. is a life science start-up based in Suita, Japan, specializing in the research and development of advanced genome editing technologies. Founded in 2018, the company focuses on utilizing CRISPR and Cas3 methods to create innovative tools for drug discovery and therapeutic applications. C4U aims to address various intractable diseases and contribute to solutions for pressing social issues across multiple sectors, including medicine, agriculture, forestry, livestock, and fisheries. By developing a robust platform for gene editing, C4U supports pharmaceutical companies in their quest for new gene therapy methods and enhances the potential for groundbreaking advancements in healthcare and beyond.

SK Fine is a pioneering company in the field of 3D printing technology, specifically focused on ceramics. It is recognized as the first to introduce a 3D printer for ceramics to the Japanese market. The company specializes in creating ceramic parts that traditional manufacturing methods cannot produce, utilizing three-dimensional CAD data provided by clients. SK Fine not only offers customized products from various materials, including resin and metal, but also develops tailored 3D printing processes for ceramic components to meet specific client requirements. Through its innovative approach, SK Fine is advancing the capabilities of ceramic manufacturing, providing unique solutions that cater to diverse needs in the industry.

Aipore Inc. is a technology company based in Shibuya-ku, Tokyo, Japan, that specializes in the development of nanopore sensors. Founded in 2018, Aipore utilizes semiconductor microfabrication technology to create Internet of Things (IoT) sensors capable of measuring and analyzing changes in ion flow. The company's innovative technology integrates various advancements, including silicon micro-electromechanical systems (MEMS), flow path surface control, and low noise amplification circuits. By employing artificial intelligence, Aipore's sensors can accurately identify particles such as viruses and microorganisms, making them suitable for a range of industrial applications, including laboratory testing, cancer detection, blood diagnostics, livestock inspection, and environmental assessment. The company aims to revolutionize fine particle measurement and enhance analytical capabilities across multiple sectors.

COTOBADESIGN, Inc. specializes in the development and delivery of dialogue artificial intelligence (AI) content. Established in 2017 and headquartered in Tokyo, Japan, the company offers innovative tools aimed at enhancing productivity in various sectors, including elderly and nursing care, business automation, and entertainment. Additionally, COTOBADESIGN provides a platform that supports the development of dialogue AI content, catering to the growing demand for automated communication solutions across different markets.

AI Samurai Inc. is a Tokyo-based company founded in 2015 that focuses on the development and sale of artificial intelligence technology. The company specializes in creating a patent examination platform that utilizes AI to evaluate patentability and conduct comprehensive patent searches. This platform supports clients in analyzing patent documents, thereby facilitating research and development efforts. In addition to its core offerings, AI Samurai also engages in patent research and technical investigation, providing valuable insights and services to enhance innovation in the field of artificial intelligence. The company also maintains a branch office in Osaka, expanding its reach within Japan.

NanoMist Technologies engages with R&D, design, and sells machines in the areas such as alcoholic beverages and food enrichment, fragrance extraction, chemical purification process, wastewater management, and deodorization process. NanoMist Technologies manufactures and sells machines such as ultrasonic atomization machine, deodorization machine, hot spring water concentration machine, solvent recovery machine, VOCs recovery machine, and granular material production machine.

C4U Co., Ltd. is a life science start-up based in Suita, Japan, specializing in the research and development of advanced genome editing technologies. Founded in 2018, the company focuses on utilizing CRISPR and Cas3 methods to create innovative tools for drug discovery and therapeutic applications. C4U aims to address various intractable diseases and contribute to solutions for pressing social issues across multiple sectors, including medicine, agriculture, forestry, livestock, and fisheries. By developing a robust platform for gene editing, C4U supports pharmaceutical companies in their quest for new gene therapy methods and enhances the potential for groundbreaking advancements in healthcare and beyond.

MediTact is Contribute to the medical society through the challenging development of medical technologies that meet patient treatment needs.

ThinkCyte, Inc. is a biotechnology company that specializes in developing an artificial intelligence-enabled, image-free visual cell sorting system, which sorts cells based on their morphology. Founded in 2016 and headquartered in Tokyo, Japan, with an additional office in San Carlos, California, ThinkCyte utilizes advanced optics and machine learning to create its ghost cytometry technology. This innovative approach allows for ultra-high throughput and content-rich analysis of single cells, facilitating research, diagnostics, and therapeutics across various medical disciplines such as drug discovery and cell therapy. The company's cell sorting technology enables researchers to identify and isolate specific cells, including rare ones, in real-time, advancing the capabilities of single-cell analysis.

Chromocenter Inc. is a biopharmaceutical company based in Yonago, Japan, established in 2005. The company specializes in developing artificial chromosome technologies, primarily focusing on applications within the life sciences sector. Chromocenter's innovative approach utilizes artificial chromosome vectors to facilitate drug discovery and the construction of stable gene expression cell lines, which are essential for high protein production. Additionally, the company offers services such as chromosome analysis and various forms of fluorescence in situ hybridization (FISH), including multicolor and monochrome analysis. Through its advanced technologies, Chromocenter aims to provide clinicians with safe and effective pharmaceuticals for treating a range of diseases.

Chromocenter Inc. is a biopharmaceutical company based in Yonago, Japan, established in 2005. The company specializes in developing artificial chromosome technologies, primarily focusing on applications within the life sciences sector. Chromocenter's innovative approach utilizes artificial chromosome vectors to facilitate drug discovery and the construction of stable gene expression cell lines, which are essential for high protein production. Additionally, the company offers services such as chromosome analysis and various forms of fluorescence in situ hybridization (FISH), including multicolor and monochrome analysis. Through its advanced technologies, Chromocenter aims to provide clinicians with safe and effective pharmaceuticals for treating a range of diseases.

Jeplan, Inc. is a Japanese company specializing in recycling technologies and systems aimed at promoting sustainable practices. Founded in January 2007 and based in Tokyo, it develops innovative solutions that cater to diverse consumer needs. The company utilizes proprietary chemical recycling technology to transform waste materials, such as food packaging and plastic PET bottles, into recycled polyethylene terephthalate (r-PET) resin and Bis(2-Hydroxyethyl) terephthalate (r-BHET) resin. These recycled materials are then used in the manufacturing of various products, including PET bottles and textiles. In addition to its technological advancements, Jeplan is involved in promoting the recycling of used uniforms and offers consulting services to businesses looking to implement recycling initiatives. Through its efforts, Jeplan aims to enhance recycling efficiency and contribute to environmental sustainability.

GlyTech, Inc. is a biotechnology company based in Kyoto, Japan, founded in 2012. It specializes in the manufacture of human-type N-glycans and employs advanced glycosylation technologies for glycopeptide and glycoprotein synthesis. The company is dedicated to producing natural glycoproteins and glycopeptides through both glycoscience and chemical synthetic methods. GlyTech provides a range of services, including licensing of glycosylated peptides and proteins, contract research and development, custom synthesis, and contract manufacturing. Additionally, it supplies standard reagents, supporting researchers in their efforts to advance human health, enhance drug development options, and expand capabilities in biotherapeutic analysis and glycoscience research.

Immunosens is a developer of electrochemical measurement devices focused on evaluating biomarkers, including genes, proteins, and cell signals through electrode reactions. The company specializes in the production of sensors that utilize disposable printable electrodes, which enhance the accuracy of analyses and measurements. These devices are aimed at supporting healthcare professionals in their diagnostic processes as well as in food safety inspections, providing reliable and precise results essential for effective decision-making in various applications.

Luxna Biotech Co., Ltd., founded in 2017 and headquartered in Suita, Japan, specializes in the development of nucleic acid drugs. The company employs innovative technologies to expedite the practical application of these drugs, offering drug discovery support services that leverage artificial nucleic acid technology. Its mission is to alleviate suffering by contributing to improved medical treatments.

Pi-Crystal Incorporation, founded in 2013 and headquartered in Osaka, Japan, specializes in the development and manufacture of printable organic semiconductor integrated circuits. The company focuses on research and development, design, and sales of organic semiconductor materials and devices, utilizing innovative technologies that differ significantly from traditional silicon semiconductors. Its products are designed for flexibility and low-cost production, making them suitable for various industrial applications. By leveraging unique materials and film formation methods, Pi-Crystal enables clients to create soft, thin, lightweight, and inexpensive devices, contributing to advancements in the Internet of Things sector.

Periotherapia is a drug discovery company focused on developing medical treatments for intractable diseases, with a primary emphasis on triple-negative breast cancer. The company aims to selectively inhibit specific pathways involved in disease progression without affecting physiological processes associated with chronic conditions such as cancer, heart failure, arteriosclerosis, renal failure, and diabetic retinopathy. By utilizing disease-specific antibodies, Periotherapia contributes to early diagnosis and precision medicine, enhancing the ability of healthcare professionals to identify and create new therapeutic options for various challenging medical conditions.

Elvez is a company focused on the research, development, and commercialization of dialogue technology. It provides a range of services, including a training management system, a WordPress plugin, and AI-based consulting services. Elvez aims to address social issues through its technology, offering solutions that are accessible via smartphones and web browsers. By leveraging AI technology, the company seeks to enhance the effectiveness of consulting services, particularly for seniors, thereby facilitating better engagement with technology.

PGV Co., Ltd., founded in September 2016 and based in Japan, specializes in the development of electroencephalogram (EEG) related technologies. The company focuses on creating innovative brain wave sensor devices, specifically patch-type electroencephalographs, which allow for the accurate measurement of brain waves in a manner similar to using a thermometer. By integrating artificial intelligence for data analysis, PGV aims to facilitate self-care through the continuous monitoring of brain activity, thereby enhancing personal health management. The company's advancements are designed to support medical professionals in delivering efficient and effective patient care through accurate data collection and machine learning applications.

Remohab Corporation, established in 2017 and based in Suita City, Japan, specializes in remote telemedicine solutions focused on cardiac rehabilitation. The company has developed an innovative system that enhances the rehabilitation process by integrating Internet of Things (IoT) and Information and Communication Technology (ICT). This system enables patients to engage in rehabilitation activities at home while remaining monitored by healthcare professionals at remote medical institutions. By facilitating a connection between home and hospital-based care, Remohab aims to improve patient outcomes and support effective health management for individuals recovering from cardiac issues.

KOTAI Biotechnologies, Inc. is a biotechnology company based in Osaka, Japan, specializing in the development of a structural modeling and analysis platform for immune cell receptors. The company's innovative technology enables the extraction of detailed structural and functional information from immune cell sequences derived from routine blood samples. This capability has significant implications for understanding resistance to infections, autoimmune diseases, and cancer. KOTAI collaborates with academic institutions and pharmaceutical companies to advance research and development, focusing on the creation of diagnostic and therapeutic methods. Their platform, known as Repertoire Builder, organizes immune receptors based on their target epitopes, utilizing sequence and structural features from B and T cell receptor models. This functionality helps delineate the functional landscape of individual donors and quantifies variations between different individuals, ultimately supporting drug discovery and improving diagnostic and prognostic capabilities.

KYSHOW Corporation, founded in 1994 and based in Osaka, Japan, operates seafood retail stores that specialize in high-quality fresh fish. The company focuses on domestically produced live natural fish sourced from Japan's coastal waters, ensuring freshness and quality for its customers. In addition to retailing fresh fish, KYSHOW also manufactures and distributes seasonal gifts, particularly midyear and year-end offerings, in collaboration with renowned department stores. This dual approach enables consumers to access fresh seafood while providing options for gift-giving, catering to both everyday and special occasion needs.

Bioworks Corporation, established in 2015 and headquartered in Tokyo, Japan, specializes in the modification and sale of polylactic acid and its derivatives. The company focuses on enhancing the properties of polylactic acid to create modified compounds that meet various industrial needs. As of December 2018, Bioworks operates as a subsidiary of TBM Co., Ltd. Through its innovative approaches in bioplastics, Bioworks aims to contribute to sustainable material solutions in the production industry.

KOTAI Biotechnologies, Inc. is a biotechnology company based in Osaka, Japan, specializing in the development of a structural modeling and analysis platform for immune cell receptors. The company's innovative technology enables the extraction of detailed structural and functional information from immune cell sequences derived from routine blood samples. This capability has significant implications for understanding resistance to infections, autoimmune diseases, and cancer. KOTAI collaborates with academic institutions and pharmaceutical companies to advance research and development, focusing on the creation of diagnostic and therapeutic methods. Their platform, known as Repertoire Builder, organizes immune receptors based on their target epitopes, utilizing sequence and structural features from B and T cell receptor models. This functionality helps delineate the functional landscape of individual donors and quantifies variations between different individuals, ultimately supporting drug discovery and improving diagnostic and prognostic capabilities.

PGV Co., Ltd., founded in September 2016 and based in Japan, specializes in the development of electroencephalogram (EEG) related technologies. The company focuses on creating innovative brain wave sensor devices, specifically patch-type electroencephalographs, which allow for the accurate measurement of brain waves in a manner similar to using a thermometer. By integrating artificial intelligence for data analysis, PGV aims to facilitate self-care through the continuous monitoring of brain activity, thereby enhancing personal health management. The company's advancements are designed to support medical professionals in delivering efficient and effective patient care through accurate data collection and machine learning applications.

KOTAI Biotechnologies, Inc. is a biotechnology company based in Osaka, Japan, specializing in the development of a structural modeling and analysis platform for immune cell receptors. The company's innovative technology enables the extraction of detailed structural and functional information from immune cell sequences derived from routine blood samples. This capability has significant implications for understanding resistance to infections, autoimmune diseases, and cancer. KOTAI collaborates with academic institutions and pharmaceutical companies to advance research and development, focusing on the creation of diagnostic and therapeutic methods. Their platform, known as Repertoire Builder, organizes immune receptors based on their target epitopes, utilizing sequence and structural features from B and T cell receptor models. This functionality helps delineate the functional landscape of individual donors and quantifies variations between different individuals, ultimately supporting drug discovery and improving diagnostic and prognostic capabilities.

Chromocenter Inc. is a biopharmaceutical company based in Yonago, Japan, established in 2005. The company specializes in developing artificial chromosome technologies, primarily focusing on applications within the life sciences sector. Chromocenter's innovative approach utilizes artificial chromosome vectors to facilitate drug discovery and the construction of stable gene expression cell lines, which are essential for high protein production. Additionally, the company offers services such as chromosome analysis and various forms of fluorescence in situ hybridization (FISH), including multicolor and monochrome analysis. Through its advanced technologies, Chromocenter aims to provide clinicians with safe and effective pharmaceuticals for treating a range of diseases.

Kyoto Drug Discovery and Development Co. Ltd., based in Kyoto, Japan, specializes in the development of innovative therapeutic drugs targeting chronic degenerative eye diseases. The company focuses on creating effective treatments for conditions such as glaucoma, central retinal artery occlusion, retinal pigmentosa, and age-related macular degeneration. By addressing these intractable eye diseases, Kyoto Drug Discovery and Development aims to provide healthcare professionals with advanced options to improve patient outcomes and manage debilitating ocular conditions.

AFI, established on December 23, 2013, in Seoul, Korea, specializes in innovative technology solutions focused on the food and life science industries. The company manufactures and sells products that utilize advanced inspection and monitoring technologies, including electric filter separation systems and rapid microbiological testing. These solutions are designed to address various needs, particularly in monitoring microbial contamination risks, thereby enhancing food safety for its clients. AFI is committed to environmental sustainability while providing effective and efficient technologies in its sector.

FunPep Co Ltd is a biotechnology company dedicated to the research and development of functional peptides, which are utilized in pharmaceuticals, cosmetics, and medical devices. The company primarily focuses on creating innovative treatments for intractable peptic ulcers and aims to produce next-generation pharmaceutical products, specifically through the use of antibody-inducing peptides. FunPep's portfolio includes a range of products, such as antibody drugs and pharmaceutical treatments, reflecting its commitment to advancing medical solutions and enhancing therapeutic options in the healthcare sector.

Matrixome Inc is a scientific research company based in Osaka, Japan, dedicated to the research and development of protein-based pharmaceutical preparations. Incorporated in 2015, the company focuses on the study of matrixosomes, a concept introduced by Professor Kiyotoshi Sekiguchi, which emphasizes the interactions between cells and their extracellular environment. Matrixome's product offerings include iMAtrix-221, a substrate designed for the purification and maintenance of cardiomyocytes; iMatrix-441, which induces endothelial progenitor cells for induced pluripotent stem cells; and iMatrix-511, a recombinant human laminin-511 E8 fragment intended for use in cell culture. Through its innovative research, Matrixome aims to provide valuable insights for biotechnology researchers and advance the field of regenerative medicine.

JTEC Corporation is a Japanese company that specializes in the design, manufacture, and sale of advanced optical and automated systems. Founded in 1993 and headquartered in Ibaraki, the company primarily produces X-ray mirrors for synchrotron radiation facilities, which are utilized in various fields such as pharmaceuticals, electronics, materials science, food, and beauty. In addition to X-ray mirrors, JTEC offers a range of products for automated cell culture systems and other automated systems across different industries. Its optical product line includes various types of mirrors, such as Kirkpatrick-Baez mirrors, Montel mirrors, and deformable mirrors, as well as mirror shaping and coating solutions. Through its innovative approach, JTEC Corporation supports scientific research and technological advancements.

Microwave Chemical Co Ltd specializes in the research, development, engineering, and licensing of microwave processes. The company offers comprehensive solutions that leverage microwave platform technology tailored to specific product characteristics. Through its innovative approach, Microwave Chemical aims to enhance industrial applications of microwave technology, providing effective and efficient methods for various processes.